Enzymatica
THE SCIENCE THAT PROTECTS

Interim Report Q2/2026

January–June 2026

Enzymatica AB develops health products based on Penzyme® technology, which contains marine enzymes. The main product is ColdZyme® – a mouth spray for colds and cold-like symptoms in the upper respiratory tract. The Group's strategy is to grow by strengthening its position in existing markets and expanding internationally through established partners. Enzymatica is headquartered in Lund and is listed on Nasdaq First North Growth Market. Certified Adviser is DNB Carnegie Investment Bank AB (publ). For more information please visit .

Enzymatica AB (publ)
Interim report, January–June 2026

Q2	H1
• Net sales reached SEK 7.1 (8.3) million.	• Net sales reached SEK 18.6 (20.6) million.
• The operating result totaled SEK -12.6 (-14.9) million.	• The operating result totaled SEK -26.2 (-32.9) million.
• Earnings per share, basic and diluted, were SEK -0.05 (-0.06).	• Earnings per share, basic and diluted, were SEK -0.11 (-0.13).
• Cash flow from operating activities totaled SEK -11.7 (-21.3) million.	• Cash flow from operating activities for the period totaled SEK -18.4 (-29.9) million.

Key figures

(SEK million)	Q2 2026	Q2 2025	H1 2026	H1 2025	Full year 2025
Net sales	7.1	8.3	18.6	20.6	53.9
Gross margin, %	45	53	52	63	61
Operating profit/loss	-12.6	-14.9	-26.2	-32.9	-51.4
Cash flow from operating activities	-11.7	-21.3	-18.4	-29.9	-41.0
Net debt/Net cash			1.0	43.7	32.1
Average number of employees	18	21	18	21	21

"We currently have an active pipeline of partner discussions in several of our priority markets."

Sana Alajmovic, CEO

Enzymatica AB (publ)
Interim report, January–June 2026

Significant events during the quarter

- On April 14, Enzymatica published the annual report for the 2025 financial year.
- On May 7, Enzymatica held its Annual General Meeting, during which the Board of Directors and auditor were re-elected and resolutions were passed in accordance with the proposals of the Board and the Nomination Committee.

Significant events after the quarter

- No significant events have been reported

Other events during and after the quarter

- On 9 June, Enzymatica appointed a new Nordic Marketing and Sales Director, who will assume the role in August and lead ColdZyme's commercial development and growth across the Nordic region.
- June: Enzymatica entered into a collaboration with the Dutch professional women's cycling team Unibet Rose Rockets. The partnership is part of the company's efforts to increase ColdZyme's visibility and strengthen the brand through strategic collaborations in professional sports.

CEO Sana Alajmovic:

Continued focus on international expansion and organizational strength

During the second quarter, we accelerated the implementation of our strategy. With a growing international pipeline and a strengthened commercial organization, we are positioning Enzymatica for long-term growth.

In my second quarter as CEO, we focused on building a stronger Enzymatica. We strengthened the organization, expanded our international pipeline and reviewed our consumer communication – all aimed at making ColdZyme available to more consumers and laying the groundwork for sustainable growth.

Net sales declined by 14 percent compared with the same period last year, mainly because the comparison quarter included a larger order from STADA Austria. Meanwhile, our position in the Swedish cold remedy market remains solid, with a market share of around 5.5 percent.

A strong and diversified international pipeline

Since signing the partnership with STADA for Germany and Austria in the first quarter, interest in ColdZyme has continued to rise. We are now engaged in concrete discussions with several major players in our priority markets. Each dialogue focuses on building the long-term commercial foundations for both Enzymatica and our partners.

Partnerships of this nature take time to build. The quality of the groundwork is critical to ensuring a successful launch. The initial phase of every partnership process involves extensive due diligence, where the partner engages multiple parts of its organization – from science and clinical affairs to regulatory, supply chain, marketing and finance. In parallel, we devote considerable effort to jointly setting realistic market forecasts and defining how we will collaboratively develop the category over time. This includes everything from pricing, packaging sizes and distribution channels to marketing investments, volume commitments and launch timing relative to the cold season.

Our collaboration with STADA is progressing as planned. STADA will launch the product under its own brand, and we are now preparing the market introductions ahead of the 2026/2027 cold season.

Greater focus on the Nordic region

As we advance our international expansion, we also see considerable growth potential closer to our home markets. During the quarter, we refined our Nordic strategy and identified new opportunities – initially in Finland and Iceland, where conditions are favorable for strengthening ColdZyme's market position. To seize this potential, we have expanded our commercial organization with a Nordic Marketing and Sales Director who brings extensive consumer healthcare experience and a sharp commercial mindset.

Science that builds trust

ColdZyme rests on a solid scientific foundation. Our priority now is to make this scientific documentation more accessible. We are therefore intensifying efforts to reach opinion leaders and healthcare professionals. We hold the strongest clinical evidence in our category – most recently Davison et al. (2025), published in *The Journal of Physiology*, which shows that ColdZyme can shorten the duration of a cold by half by reducing viral load by 94 percent and relieving six of eight symptoms.

During the quarter, we entered into a collaboration with the Dutch professional women's cycling team Unibet Rose Rockets. This partnership increases ColdZyme's international visibility in an environment where performance, health and recovery are the focus, exemplifying how we build the brand through relevant partnerships. When elite athletes – who have virtually no margin for catching a cold – choose ColdZyme, it further strengthens trust in the product.

Looking ahead to the next phase

We enter the second half of the year with a clear strategy, a broad international pipeline and a strengthened organization. Our ambition is to make ColdZyme a more recognized and natural choice for a wider range of consumers while continuing to build long-term partnerships.

Sana Alajmovic, CEO

Enzymatica develops innovative self-care products, based on its barrier technology platform. Enzymatica was founded in 2007, has its head office in Lund, Sweden, and has been listed on the Nasdaq First North Growth Market since 2015.

The main product is the ColdZyme mouth spray – a spray used at the first signs of a cold. ColdZyme is sold in Sweden, the United Kingdom and Iceland through the company's own contract organizations, while distribution in other markets takes place through partnership agreements with leading consumer healthcare companies. Developing additional international partnerships remains an important part of Enzymatica's growth strategy.

Research

Enzymatica's research is conducted in collaboration with leading universities and research groups. The company's products are evaluated both in independent research studies and in studies initiated by Enzymatica. The most recent independent studies, conducted by researchers at the University of Kent and the Medical University of Vienna, were published in *The Journal of Physiology* in February 2025.

The randomized, double-blind, placebo-controlled study represents an important part of Enzymatica's strategy for continued international expansion and the relaunch of ColdZyme in Europe. Together with the MDR certification that ColdZyme received in 2024, it reinforces the company's ability to establish the product in new markets.

In the United Kingdom, the clinical study also serves as important support for marketing ColdZyme, as independent clinical documentation is required to communicate the product's claims directly to consumers.

Building on this clinical documentation, Enzymatica continues to refine the product's positioning, bolster its product claims within current regulatory requirements and identify the most effective commercial opportunities for continued international growth.

Seasonal variations

Sales of cold products are affected by seasonal variations. In Europe and other northern markets, the cold season usually begins in late autumn and subsides in March–April.

Financial targets

In connection with the appointment of the new CEO, the Board has initiated a review of Enzymatica's financial targets. In light of this, the previously communicated EBIT target of at least approximately SEK 170 million by the end of 2027 is under review. Updated targets are expected to be presented in the latter part of 2026.

ColdZyme Eucalyptus was launched on the Swedish market in October 2025 and is the latest addition to the ColdZyme range.

Financial overview – April-June 2026

Sales and market

Consolidated net sales for the second quarter of 2026 came in at SEK 7.1 million (8.3), a decrease of 13.7% compared with the same period in 2025. Adjusted for currency fluctuations, sales decreased by 13.6%. Currency effects impacted sales by -0.1%.

The lower sales were mainly due to the comparison period in the previous year including a larger delivery to a partner. Excluding this delivery, sales were on par with the previous year.

Net sales in Sweden were in line with the corresponding period last year. During the quarter, the cold remedy market at Swedish pharmacies declined by 1.3% in value compared with the same quarter in 2025. At the same time, pharmacy sales of ColdZyme in Sweden increased by 4.4% in value, resulting in a 0.3 percentage point increase in market share within the cold category.

Sales of ColdZyme in the United Kingdom decreased by 7% during the quarter to SEK 0.9 million compared with the same quarter in the previous year.

Performance

Gross profit for the quarter totaled SEK 3.2 million, compared with SEK 4.4 million for the second quarter last year, corresponding to a margin of 45% (53). Enzymatica has experienced variations in gross margins between individual quarters. The quarter’s gross margin was negatively affected by a lower-than-planned production rate, which increased the cost of goods sold.

Total operating expenses for the quarter decreased to SEK 16.1 (19.2) million. The lower costs were mainly attributable to lower selling and research and development expenses. No expenses for development projects were capitalized during the quarter (0). Other income and operating expenses totaled SEK 0.2 million (-0.1) net.

The consolidated operating loss was SEK -12.6 (-14.9) million. Net financial income and expenses for the period amounted to SEK 0.0 (-0.5) million. The difference was mainly due to decreased translation effects. Tax expenses for the period were SEK 0.3 million (0.0). Impairment charges totaled SEK 2.3 (1.3) million.

Research, development and other investments

Total consolidated research and development expenses amounted to SEK 3.2 (3.9) million for the second quarter.

The Group's investments in property, plant and equipment and intangible assets for the quarter totaled SEK 0.0 (0) million, of which SEK 0 (0) million are intangible assets. The investments of SEK 15,4 million refer mainly to the capitalization of right-of-use assets related to lease agreements for the premises in Iceland.

Sales

Consolidated net sales in the first half of the year came in at SEK 18.6 (20.6) million – a 9.6% year-on-year decrease compared with the same period in 2025. Adjusted for currency fluctuations, sales decreased by 8.8%.

Net sales in Sweden decreased by 11.8% during the first half of 2026. At the same time, pharmacy sales of ColdZyme in Sweden increased by 2.2% in value, compared with a 1.9% decline for the overall cold category.

Performance

Gross margin in first half of the year was 52% (63). Enzymatica has experienced variations in gross margins between individual quarters. The period's gross margin was negatively affected by a lower-than-planned production rate, which increased the cost of goods sold.

Total operating expenses for the first half of the year amounted to SEK 36.0 (46.0) million. The decrease is primarily due to lower research and development expenses, as well as selling expenses. No expenses for development projects were capitalized during the period SEK 0 (0) thousand.

The consolidated operating loss was SEK -26.2 (-32.9) million. Net financial income amounted to SEK 0.2 million (0.2) and the tax expense for the year was SEK 0.4 million (0.2). Impairment charges totaled SEK 3.6 (2.7) million. The result for the period was SEK -26.4 million (-32.5).

Research, development and other investments

Total consolidated research and development expenses amounted to SEK 6.0 million (9.1).

The Group's investments in property, plant and equipment and intangible assets totaled SEK 0.1 (0.0) million, of which SEK 0 (0) million are intangible assets. The investments of SEK 15,4 million refer mainly to the capitalization of right-of-use assets related to lease agreements for the premises in Iceland.

Funding and cash flow

The Group's available funds at the end of the period totaled SEK 22.7 million (46.9), of which SEK 13.1 million (45.3) consisted of cash and cash equivalents, SEK 1.6 million (1.6) of unused credit facilities and SEK 8.0 million of unused loan facilities.

Cash flow from operating activities from January through June 2026 totaled SEK -18.4 (-29.9) million. Cash flow from operating activities for Q2 came in at SEK -11.7 (-21.3) million. Total cash flow for the period amounted to SEK -20.0 (-29.9) million. The improved cash flow is a result of both lower operating expenses and reduced capital tied up in working capital.

Parent company

The parent company is responsible for group management and all operational activities, with the exception of enzyme production and the part of research and development that take place within the subsidiary Enzymatica ehf.

The parent company's sales for the first half of 2026 reached SEK 17.0 (19.5) million. Loss before tax came in at SEK -28.6 (-32.0) million. The parent company's investments in property, plant & equipment and intangible assets for the first half of the year totaled SEK 0 (0) million and cash flow was SEK -18.1 (-30.5) million. Please see the consolidated figures for more information.

Staff

The number of people employed by the Group, converted to full-time positions, was 18 (21) at the end of the period. The employees included 5 (8) men and 13 (13) women.

Other information

The Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the following subsidiaries: Enzymatica ehf (corporate identity no. 6406830589), with its head office in Reykjavik, Iceland, and Enzymatica Care AB (corporate identity no. 556701- 7495), with its head office in Lund, Sweden.

Accounting policies

This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in compliance with International Financial Reporting Standards (IFRS) as adopted by the EU, the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 1 Accounting for Groups. The parent company's annual report has been prepared in compliance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. Disclosures in accordance with IAS 34. 16A are incorporated in the financial statements and their accompanying notes, as well as in other parts of this interim report.

The recognition and measurement policies applied in the 2025 Annual Report have been applied in this interim report as well. The amendments to IFRS standards that became effective in 2026 have not had a material impact on the Group's earnings or financial position. Apart from IFRS 18, which takes effect in 2027, no material impact on the Group's financial statements is expected from new or amended standards that have not yet entered into force. IFRS 18 will affect presentation and disclosures.

Segment reporting

Enzymatica's operations currently include only one operating segment: medical devices. Please see the consolidated income statement and balance sheet for the reporting on this operating segment.

Audit

This report was not reviewed by the Group's auditors.

Incentive programs

The 2024 Annual General Meeting resolved on the warrant-based incentive program 2024/2027, comprising a maximum of 2,700,000 warrants for employees and consultants. A total of 2,130,000 warrants have been allotted and subscribed for during 2024 and 2025. Each warrant entitles the holder to subscribe for one new share at an exercise price of SEK 11.97 during the period June 1–June 30, 2027. Upon full exercise, the maximum dilution effect amounts to approximately 0.87%.

An Extraordinary General Meeting held on August 22, 2025 resolved on the warrant-based incentive program 2025/2028, comprising a maximum of 2,000,000 warrants for employees and consultants. A total of 1,000,000 warrants have been allotted and subscribed for. Each warrant entitles the holder to subscribe for one new share at an exercise price of SEK 4.82 during the period October 1–December 31, 2028. Upon full exercise, the maximum dilution effect amounts to approximately 0.82%.

Related-party transactions

On April 8, 2026, Enzymatica AB signed a loan facility totaling SEK 8 million with Chairman of the Board Bengt Baron (SEK 2 million) and Board members Mats Andersson (SEK 4 million) and Helene Willberg (SEK 2 million), through their companies. The loan facility runs for three years with 10% interest and a 2% commitment fee. The loan facility has been entered into on market terms and remained undrawn during the quarter.

Information about risks and uncertainties

Enzymatica's operations remain exposed to several operational, commercial and financial risks. These include the company's ability to secure access to capital, develop and maintain commercial partnerships, and manage production and the supply chain in line with its business development.

The company continuously works to ensure an appropriate capital structure and strong financial preparedness to enable the execution of its long-term strategy. If access to external financing were to deteriorate, or if capital could not be raised on acceptable terms, this could affect the company's ability to carry out planned activities.

Enzymatica's continued expansion depends on successful collaborations with commercial partners. Ongoing dialogues are being held with both existing and new partners with the aim of strengthening the company's market presence and re-establishing ColdZyme in selected key markets in Europe.

Production is based on a combination of in-house manufacturing and external manufacturing and supply partners. Disruptions in production, limited access to raw materials or other deviations in the supply chain may temporarily affect the company's delivery capacity.

Other risks to which the business is exposed include currency-related risks as well as changes in laws, regulations and regulatory requirements. Apart from this, no material changes have occurred regarding the risks and uncertainties described in the 2025 Annual Report.

Other information

Upcoming financial information

Interim report, Jan–Sep 2026	October 29, 2026
Year-end report 2026	February 18, 2027
Annual Report 2026	Week 15, 2027
Interim report, Jan–Mar 2027	28 April 2027
AGM	May 13, 2027

The interim reports and annual report are available at www.enzymatica.com.

Interim report signatures

Lund, July 16, 2026

Sana Alajmovic
CEO

For questions about this report, please contact:

Sana Alajmovic, CEO, Enzymatica AB
0723 89 33 96 | sana.alajmovic@enzymatica.com

Holger Lembrér, CFO, Enzymatica AB
0722-30 77 10 | holger.lembrer@enzymatica.com

Publication

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on Thursday, July 16, 2026.

Street address

Enzymatica AB (publ), corp. ID no. 556719-9244.

Mailing address: Ideon Science Park, 223 70 Lund, Sweden
Street address: Scheelevägen 19, Ideon, Lund, Sweden
Tel: +46 46-286 31 00 | info@enzymatica.se | www.enzymatica.se

Enzymatica AB (publ) is listed on the Nasdaq First North Growth Market. The Company is traded under the ticker symbol ENZY and ISIN code SE0003943620. Certified Adviser is DNB Carnegie Investment Bank AB (publ), certifiedadviser@carnegie.se

Condensed consolidated statement of comprehensive income

All amounts in SEK thousand	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating income					
Net sales	7 147	8 282	18 587	20 562	53 903
Cost of goods sold	-3 908	-3 902	-8 899	-7 708	-20 778
Gross profit	3 239	4 380	9 688	12 854	33 126
Sales & Marketing expenses	-2 378	-4 609	-9 055	-15 912	-27 438
Administrative expenses	-10 528	-10 686	-20 960	-20 925	-42 236
Research and development costs	-3 158	-3 940	-5 966	-9 134	-15 659
Other operating income	309	317	404	739	1 296
Other operating costs	-122	-384	-320	-535	-457
Operating profit/loss	-12 639	-14 921	-26 210	-32 913	-51 367
Profit/loss from financial items					
Interest income and similar profit/loss items	232	574	567	592	759
Interest expenses and similar profit/loss items	-254	-115	-346	-374	-1 231
Profit/loss after financial items	-12 661	-14 461	-25 989	-32 695	-51 839
Tax expenses	-307	5	-434	234	-51
Profit/loss for the period	-12 968	-14 456	-26 423	-32 461	-51 890
Other comprehensive income:					
Items that have been redirected or may be included in the profit/loss:					
Translation difference of subsidiaries	297	223	465	-180	-695
Total other comprehensive income, net of tax	297	223	465	-180	-695
Total comprehensive income for the period	-12 671	-14 233	-25 958	-32 641	-52 586
Share attributable to parent company shareholders	-12 671	-14 233	-25 958	-32 641	-52 586

Earnings per share

	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Earnings per share, SEK (basic and diluted)	-0,05	-0,06	-0,11	-0,13	-0,21
Equity per share, SEK	0,40	0,59	0,40	0,59	0,51
Equity-asset ratio, %	79%	93%	79%	93%	87%
Number of outstanding shares	242 735 108	242 735 108	242 735 108	242 735 108	242 735 108
Average number of outstanding shares (basic and diluted)	242 735 108	242 735 108	242 735 108	242 735 108	242 735 108

Key financial indicators

Earnings per share
Profit/loss for the period in relation to average weighted number of shares.

Equity per share
Equity in relation to number of shares at the end of the period.

Equity ratio
Equity in relation to total assets.

Net cash/Net debt
Cash and cash equivalents less interest-bearing current and non-current liabilities. A negative amount means net debt.

Quarterly review by auditors

All amounts in SEK thousand	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Net sales	7 147	11 440	18 334	15 007	8 282	12 280
Gross profit/loss	3 239	6 449	11 029	9 242	4 380	8 473
Gross margin in %	45%	56%	60%	62%	53%	69%
Operating costs	-16 065	-19 917	-21 818	-17 543	-19 235	-26 737
Operating profit/loss	-12 639	-13 571	-10 223	-8 231	-14 921	-17 992
Profit/loss for the period	-12 968	-13 455	-11 027	-8 403	-14 456	-18 005
Cash flow	-12 936	-7 099	125	-12 215	-21 360	-8 541

Condensed consolidated statement of financial position

All amounts in SEK thousand	2026-06-30	2025-06-30	2025-12-31	2024-12-31
Assets				
Intangible assets	63 181	65 187	64 181	66 192
Right-of-use assets	14 167	1 588	1 022	2 201
Tangible assets	8 776	10 869	9 343	12 198
Financial assets	2 063	2 839	2 407	2 637
Inventories	14 470	16 836	18 915	16 708
Trade receivables	4 350	6 149	9 997	12 090
Other receivables	4 479	5 929	2 979	7 985
Cash and cash equivalents	13 145	45 289	33 134	75 212
Total assets	124 632	154 686	141 978	195 224
Equity and liabilities				
Equity	98 215	143 728	124 173	176 369
Non-current lease liabilities	11 516	457	8	1 022
Current lease liabilities	2 651	1 132	1 015	1 179
Trade payables	1 901	3 799	8 750	9 812
Other liabilities	10 348	5 570	8 033	6 842
Total equity and liabilities	124 632	154 686	141 978	195 224

Condensed consolidated statement of changes in equity

All amounts in SEK thousand	2026-06-30	2025-06-30	2025-12-31	2024-12-31
Opening balance	124 173	176 369	176 369	76 609
New share issue	-	-	-	159 147
Issue expenses related to New share issue	-	-	-	-7 424
Effect of option program	-	0	390	115
Total comprehensive income for the period	-25 958	-32 641	-52 586	-52 077
Closing balance	98 215	143 728	124 173	176 369

Condensed consolidated statement of cash flows

All amounts in SEK thousand		Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating profit/loss		-12 639	-14 921	-26 210	-32 913	-51 367
Adjustments for non-cash items	Note 1	1 898	1 029	3 599	3 013	6 231
Financial items		258	460	221	218	-472
Cash flow from operating activities before changes in working capital		-10 482	-13 432	-22 390	-29 682	-45 608
Changes in working capital		-1 205	-7 900	3 946	-190	4 636
Cash flow from operating activities		-11 687	-21 332	-18 444	-29 873	-40 972
Acquisition/disposal of property, plant & equipment		0	267	-75	585	-231
Cash flow from investing activities		0	267	-75	585	-231
Rights Issue		-	-	-	-	-
Issued warrants		-	-	-	0	390
Transaction costs attributable to new share issue		-	-	-	-	-
Change in bank/overdraft facilities/leasing		-1 249	-295	-1 516	-613	-1 179
Cash flow from financing activities		-1 249	-295	-1 516	-613	-789
Total cash flow for the period		-12 936	-21 360	-20 035	-29 901	-41 991
Cash and cash equivalents at start of period		26 056	66 616	33 134	75 212	75 212
Translation difference cash and cash equivalents		25	33	46	-22	-87
Cash and cash equivalents at end of period		13 145	45 289	13 145	45 289	33 134

Note 1: Primarily related to depreciation.

Parent company income statement

All amounts in SEK thousand	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating income					
Net sales	6 458	7 812	16 970	19 519	51 265
Cost of goods sold	-7 548	-6 889	-15 816	-13 701	-35 682
Gross profit	-1 090	923	1 154	5 818	15 583
Sales & Marketing expenses	-2 260	-4 351	-8 621	-14 909	-25 820
Administrative expenses	-6 755	-6 865	-12 789	-13 335	-26 349
Research and development costs	-4 511	-4 626	-8 644	-10 019	-16 369
Other operating income	99	256	338	262	79
Other operating costs	-122	-499	-320	-526	-123
Operating profit/loss	-14 639	-15 162	-28 882	-32 708	-52 999
Profit/loss from financial items					
Interest income and similar profit/loss items	144	794	354	1 033	1 642
Interest expenses and similar profit/loss items	-64	-94	-86	-332	-1 120
Results from subsidiaries	-	-	-	-	-
Write-down subsidiaries	-	-	-	-	-
Profit/loss after financial items	-14 559	-14 462	-28 615	-32 008	-52 477
Tax expenses	-	-	-	-	-
Profit/loss for the period	-14 559	-14 462	-28 615	-32 008	-52 477

Parent company balance sheet

All amounts in SEK thousand	2026-06-30	2025-06-30	2025-12-31	2024-12-31
Assets				
Intangible assets	875	2 880	1 874	3 886
Tangible assets	28	49	38	31
Financial assets	7 452	7 452	7 452	7 452
Inventories	13 261	14 198	17 638	13 823
Trade receivables	3 933	5 807	9 793	11 365
Receivables from group companies	461	10 091	5 162	9 744
Other receivables	2 014	4 146	2 005	6 430
Cash and bank balances	12 439	43 509	30 490	73 987
Total assets	40 462	88 132	74 452	126 717
Equity and liabilities				
Equity	32 019	80 713	60 633	112 721
Long-term interest-bearing liabilities	-	-	-	-
Current interest-bearing liabilities	-	-	-	-
Liabilities to group companies	187	-	-	-
Trade payables	1 740	3 328	8 164	8 783
Other liabilities	6 516	4 091	5 654	5 213
Total equity and liabilities	40 462	88 132	74 452	126 717

www.enzymatica.com